^○Akinori Nakamura (National Hospital Organization Matsumoto Medical Center, Japan)

^○Daigo Miyazaki^1,2, Naoko Shiba³, Mitsuto Sato^1,5, Yuji Shiba³, Yusuke Echigoya⁴, Toshifumi Yokota⁴, Yoshitaka Mizobe⁵, Yoshitsugu Aoki⁵, Shinichi Takeda⁵, Akinori Nakamura^1,6 (1.Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Japan, 2.Intractable Disease Care Center, Shinshu University Hospital, Japan, 3.Institute for Biomedical Sciences, Shinshu University, 4.Department of Medical Genetics, School of Human Development, Faculty of Medicine and Dentistry, University of Alberta, 5.Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), 6.Department of Neurology, National Hospital Organization Matsumoto Medical Center)

^○Yutaka Ohsawa¹, Shunichi Shirakawa¹, Shin-ichiro Nishimatsu², Yoshihide Sunada¹ (1.Neurology, Kawasaki Medical School, Japan, 2.Natural Science, Kawasaki Medical School)

^○Ayuka Murakami^1,2, Tomoyuki Kazuta^1,2, Seiya Noda^1,2, Seigo Kimura^1,2, Haruki Koike¹, Masahisa Katsuno¹ (1.Nagoya University Hospital, Department of Neurology, Japan, 2.National Hospital Organization Suzuka National Hospital, Department of Neurology, Japan)

^○Mika Suga^1,2, Takayuki Kondo^1,2,3, Keiko Imamura^1,2,3, Yasue Okanishi¹, Ran Shibukawa^1,2, Yukako Sagara¹, Kayoko Tsukita^1,2, Takako Enami^2,3, Takashi Kimura⁴, Haruhisa Inoue^1,2,3 (1.iPSC-baced Drug Discovery and Development Team, RIKEN BioResource Research Center (BRC), Japan, 2.Dept. of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University, Japan, 3.Medical-risk Avoidance based on iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP), 4.Division of Neurology, Dept. of Internal Medicine, Hyogo College of Medicine)

^○Satoshi Yamashita, Kentaro Hara, Nozomu Tawara, Mitsuharu Ueda (Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Japan)